TriSalus Q1 revenue up 116% to $6.5M, secures $50M OrbiMed debt facility

TriSalus Life Sciences, Inc.

2024-Q1 EPS reported -$0.60 revenue$6,457,000

Revenue of $6.5M in Q1 2024, up 116% YoY; gross margin improved to 85% from 78%.
Net loss available to common stockholders was $13.2M ($0.60 per share) vs $8.3M loss in Q1 2023.
Closed $25M initial draw on up to $50M debt financing with OrbiMed; expects runway through end of 2024.
Appointed Liselotte Hyveled, Chief Patient Officer at Novo Nordisk, to Board of Directors.
Management reiterates full-year revenue growth guidance exceeding 50%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TriSalus Life Sciences, Inc. reported first quarter ended March 31, 2024 results: revenue $6.5 million, net income $13.2 million, EPS $0.60.

Period: first quarter ended March 31, 2024
Revenue: $6.5 million
Net income: $13.2 million
EPS: $0.60
Result: reported results

Exact text from the filing

TriSalus Reports Q1 2024 Financial Results and Business Update · Reported revenues of $6.5 million in 1Q24, up 116% compared to 1Q23 · Reported Gross Margin of 85% in 1Q24

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

TriSalus Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-061631

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.